Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Oct;78(3):181-7.
doi: 10.1007/BF02983793.

The pathophysiology of acute graft-versus-host disease

Affiliations
Review

The pathophysiology of acute graft-versus-host disease

James L M Ferrara et al. Int J Hematol. 2003 Oct.

Abstract

The pathophysiology of acute graft-versus-host disease (GVHD) is a complex process that can be conceptualized in three phases. In the first phase, high-dose chemoradiotherapy causes damage to host tissues, including a self-limited burst of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin 1. These cytokines activate host antigen-presenting cells (APCs). In the second phase, donor T-cells recognize alloantigens on host APCs. These activated T-cells then proliferate, differentiate into effector cells, and secrete cytokines, particularly interferon (IFN)-gamma. In the third phase, target cells undergo apoptosis mediated by cellular effectors (eg, donor cytotoxic T-lymphocytes) and inflammatory cytokines such as TNF-alpha. TNF-alpha secretion is amplified by stimuli such as endotoxin that leaks across damaged gastrointestinal mucosa injured by the chemoradiotherapy in the first phase. TNF-alpha and IFN-gamma cause further injury to gastrointestinal epithelium, causing more endotoxin leakage and establishing a positive inflammatory feedback loop. These events are examined in detail in the following review.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blood. 1998 Nov 15;92(10):3960-7 - PubMed
    1. J Immunol. 1988 Oct 15;141(8):2629-34 - PubMed
    1. Cancer Res. 1998 Mar 1;58(5):933-9 - PubMed
    1. Curr Opin Immunol. 1998 Oct;10(5):581-7 - PubMed
    1. Eur J Clin Invest. 1993 Sep;23(9):540-5 - PubMed

MeSH terms

LinkOut - more resources